Clinical effect on the treatment of proliferative diabetic retinopathy with minimally invasive vitrectomy combined with compexip vitreous injection
Objective To investigate the advantages and efficacy of minimally invasive vitrectomy combined with vitreous cavity injection of Compazine in the treatment of proliferative diabetic retinopathy.Methods A total of 66 patients with proliferative diabetes retinopathy admitted to Shuyang Hospital from March 2020 to October 2022 were selected as the research objects.They were randomly divided into two groups by the method of random number table.The control group(33 cases)were treated with minimally invasive vitrectomy.The observation group(33 cases)received a combination of drug injection(Conbercept intravitreal injection)on the basis of the control group.Compare two groups of eye indicators and perioperative clinical indicators.Results Before treatment,there was no statistically significant difference in visual acuity,intraocular pressure,and macular fovea thickness between the two groups of patients(P>0.05).After treatment,the eye indicators of both groups improved compared to before treatment,and the observation group showed significant differences in visual acuity,decreased intraocular pressure,and decreased macular fovea thickness compared to the control group(P<0.05).The observation group patients had less time and amount of bleeding during surgery,postoperative edema absorption,fundus hemorrhage absorption,and exudate absorption than the control group,with statistically significant differences(P<0.05).Conclusion For patients with proliferative diabetic retinopathy after the combined program,i.e.,minimally invasive vitrectomy with the intravitreal injection of drugs(Compazine),the efficacy of the treatment is certain,and can effectively promote the recovery of the patient's visual acuity and regulation of intraocular pressure,which is worthy of use and promotion.
万方数据
维普
